

TURKISH INFLAMMATORY BOWEL DISEASE SOCIETY RECOMMENDATIONS ON SELECTED TOPICS OF CROHN'S DISEASE TÜRK İNFLAMATUVAR BARSAK HASTALIKLARI DERNEĞİNİN CROHN HASTALIĞI İLE İLGİLİ SEÇİLMİŞ KONULARDA ÖNERİLERİ

Ülkü DAĞLI

Head of the Inflammatory Bowel Disease Association

Crohn's disease is a chronic disease of the gastrointestinal tract which develops due to genetic and environmental factors and lasts life-long. While it is more prevalent in the developed world, in recent years it has been increasing in developing countries, as well. In an epidemiological study carried out in Turkey by the "Inflammatory Bowel Disease Society" through utilizing hospital records (1), the incidence of Crohn's disease was determined as 1.4 and the prevalence as 7.7. These rates were underestimations and were higher than in Asia but lower than in Europe.

One of the goals of the Inflammatory Bowel Disease Society is to develop guidelines for the diagnosis, management and follow up of ulcerative colitis and Crohn's disease. During guideline development efforts, the "Guideline for the diagnosis, management and follow up of bowel diseases" was published by ECCO. Since each topic was discussed in detail in this guideline, making extra efforts for a complete guideline would be expensive and time consuming and was considered as unnecessary. However in the ECCO guideline, it was determined that there were some vague areas for our region and our patients, so a decision was made to analyse these issues and develop national recommendations within the 3e framework. The 3e program is a group work integrating evidence, expertise and exchange affairs.

The course of developing national recommendations was as follows:

1. A scientific committee was formed during the administrative board meeting (January 2009) of the Inflammatory Bowel Disease Society. The goals and the methodology were determi-

ned in the first meeting.

2. Just after the meeting, ECCO recommendations were reported to the gastroenterology association members and they were asked to forward their opinions regarding the topics that should be taken up for Turkey.
3. In February 2009, questions concerning the diagnosis, management and follow up of Crohn's disease were determined and principle investigators were selected. The questions were formulated and adapted for the study.

The topics that were approved for the study were as follows:

- A. What is the value and priority of endoscopic and radiologic procedures in evaluating other segments of the gastrointestinal tract among patients diagnosed with Crohn's disease through ileocolonoscopy and histopathology?
- B. Which test is more valid for the diagnosis of amoebiasis among Crohn's cases?
- C. Which test is more valid for the diagnosis of CMV enterocolitis among Crohn's cases?
- D. For the differential diagnosis of intestinal tuberculosis:
 - a. What should be the minimum number of biopsies?
 - b. Is tissue culture needed?
 - c. Should PCR be performed?
 - d. What is the diagnostic value of PPD compared with IGRA?

Address for correspondence: Ülkü DAĞLI

Department of Gastroenterology

Abant İzzet Baysal University, School of Medicine

Bolu, Turkey

Phone: + 90 374 253 46 56 • Fax: + 90 374 253 46 15

E-mail: udagli@hotmail.com

doi: 10.4318/tjg.2010.0059

Table 1. Levels of evidence and grades of recommendation based on the Oxford Centre for Evidence Based Medicine

Level	Individual study	Technique
1a	Systematic review (SR) with homogeneity of level 1 diagnostic studies	Systematic review (SR) with homogeneity of randomised controlled trials (RCTs)
1b	Validating cohort study with good reference standards	Individual RCT (with narrow confidence interval)
1c	Specificity is so high that a positive result rules in the diagnosis ("SpPin") or sensitivity is so high that a negative result rules out the diagnosis ("SnNout")	All or none
2a	SR with homogeneity of level >2 diagnostic studies	SR (with homogeneity) of cohort studies
2b	Exploratory cohort study with good reference standards	Individual cohort study (including low quality RCT; for example, <80% follow up)
2c		"Outcomes" research; ecological studies
3a	SR with homogeneity of 3b and better studies	SR with homogeneity of case-control studies
3b	Non-consecutive study; or without consistently applied reference standards	Individual case-control study
4	Case-control study, poor or non-independent reference standard	Case series (and poor quality cohort and case-control studies)
5	Expert opinion without explicit critical appraisal, or based on physiology, bench research, or "first principles"	Expert opinion without explicit critical appraisal, or based on physiology, bench research, or "first principles"

Grades of recommendation

- A** consistent level 1 studies
- B** consistent level 2 or 3 studies or extrapolations from level 1 studies
- C** level 4 studies or extrapolations from level 2 or 3 studies
- D** level 5 evidence or troublingly inconsistent or inconclusive studies of any level

- E.** What are the methods that should be used at follow ups and at what intervals they should be used during the remissions?
- a. Clinic?
 - b. Laboratory (CRP)?
 - c. Endoscopic?
- F.** When and how often should DEXA be used for the diagnosis and follow up of osteoporosis in Crohn's disease?
- G.** What is the value of Anti-TNF agents in the management of luminal (inflammatory type) of Crohn's disease?
- 4.** The study groups performed systematic literature search through using appropriate keywords in medline/pubmed and the Cochrane database. The evidence was ranked according to the "Oxford Centre of Evidence Based Medicine" in terms of Evidence Level (EL), and Re-

commendation Grade (RG) (Table 1) (2).

- 5.** The study groups and 60 gastroenterology specialists met at 13-14th November 2009 for forming the last version of the recommendations. The recommendations were presented and voted. The recommendations that were voted by more than 80% and agreed upon by more than 80% participants were accepted as the national recommendations. Each recommendation was ranked according to the "Oxford Centre of Evidence Based Medicine" (RG) (Table 1).

The final document is written by the principle investigator for each topic. The national recommendations are presented in the boxes.

Acknowledgements: The study was supported by Abbott Laboratories. We as Turkish Inflammatory Bowel Diseases Assembly would like to thank Dr. Gülen HATEMİ for her help and comments on this work.

REFERENCES

1. Dağlı Ü. Epidemiology and genetics of inflammatory bowel disease in Turkey. Falk symposium 159. IBD 2007-Achievements in research and clinical practice: 3-12
2. Centre of evidence based medicine, Oxford. Levels of evidence and grades of recommendation.